Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LAP3 | P28838 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29867871 | 0.90 | ALDH1A1 (0.47) | ALDH1A1MAPTLAP3MEN1LMNA | |
| SCHEMBL31257064 | 0.88 | PTGS1 (0.43) | ALDH1A1MAPTLAP3LMNAOPRD1 | |
| SCHEMBL29590916 | 0.88 | ALDH1A1 (0.51) | ALDH1A1MAPTLAP3MEN1LMNA | |
| SCHEMBL30051649 | 0.87 | TERT (0.51) | ALDH1A1MAPTLAP3MEN1LMNA | |
| SCHEMBL7150981 | 0.86 | MAPT (0.53) | ALDH1A1MAPTLAP3MEN1LMNA | |
| SCHEMBL7553789 | 0.86 | MAPT (0.53) | ALDH1A1MAPTLAP3MEN1LMNA | |
| SCHEMBL29871252 | 0.86 | MME (0.45) | OPRD1OPRM1OPRK1MME | |
| SCHEMBL30808874 | 0.85 | OPRD1 (0.49) | ALDH1A1MAPTLAP3MEN1LMNA | |
| SCHEMBL31456588 | 0.85 | ACE (0.50) | ALDH1A1MAPTLMNAOPRD1OPRM1 | |
| SCHEMBL14436768 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTLAP3MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ALDH1A1 3596/4885MAPT 3330/4885LAP3 38/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ALDH1A1 4110/4885MAPT 4191/4885LAP3 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.